{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T19:48:17Z","timestamp":1792439297387,"version":"4.5.0"},"reference-count":6,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2023,8,22]]},"abstract":"<jats:p>This study assesses the use of mifepristone plus misoprostol for miscarriage management among commercially insured adults in the US.<\/jats:p>","DOI":"10.1001\/jama.2023.13628","type":"journal-article","created":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T15:30:59Z","timestamp":1689953459000},"page":"766","source":"Crossref","is-referenced-by-count":9,"title":["Trends in the Use of Mifepristone for Medical Management of Early Pregnancy Loss From 2016 to 2020"],"prefix":"10.1001","volume":"330","author":[{"given":"Elise W.","family":"Boos","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Horta","sequence":"additional","affiliation":[{"name":"Department of Health Policy, Vanderbilt University School of Medicine, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Thompson","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacie B.","family":"Dusetzina","sequence":"additional","affiliation":[{"name":"Department of Health Policy, Vanderbilt University School of Medicine, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley A.","family":"Leech","sequence":"additional","affiliation":[{"name":"Department of Health Policy, Vanderbilt University School of Medicine, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"5","key":"jld230050r1","doi-asserted-by":"publisher","first-page":"e197","DOI":"10.1097\/AOG.0000000000002899","article-title":"ACOG Practice Bulletin No. 200: early pregnancy loss.","volume":"132","author":"American College of Obstetricians and Gynecologists\u2019 Committee on Practice Bulletins\u2014Gynecology","year":"2018","journal-title":"Obstet Gynecol"},{"issue":"23","key":"jld230050r2","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1056\/NEJMoa1715726","article-title":"Mifepristone pretreatment for the medical management of early pregnancy loss.","volume":"378","author":"Schreiber","year":"2018","journal-title":"N Engl J Med"},{"issue":"10253","key":"jld230050r3","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/S0140-6736(20)31788-8","article-title":"Mifepristone and misoprostol versus misoprostol alone for the management of missed miscarriage (MifeMiso): a randomised, double-blind, placebo-controlled trial.","volume":"396","author":"Chu","year":"2020","journal-title":"Lancet"},{"issue":"3","key":"jld230050r4","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.1594","article-title":"Cost-effectiveness of mifepristone pretreatment for the medical management of nonviable early pregnancy: secondary analysis of a randomized clinical trial.","volume":"3","author":"Nagendra","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"1","key":"jld230050r5","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.contraception.2021.04.017","article-title":"US clinicians\u2019 perspectives on how mifepristone regulations affect access to medication abortion and early pregnancy loss care in primary care.","volume":"104","author":"Srinivasulu","year":"2021","journal-title":"Contraception"},{"issue":"10","key":"jld230050r6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2301813","article-title":"Alliance for Hippocratic Medicine v FDA\u2014Dobbs\u2019s collateral consequences for pharmaceutical regulation.","volume":"388","author":"Zettler","year":"2023","journal-title":"N Engl J Med"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2807775\/jama_boos_2023_ld_230050_1692722175.68401.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T17:00:29Z","timestamp":1692723629000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2807775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,22]]},"references-count":6,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8,22]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2023.13628","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,22]]}}}